Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune

This page shows the latest Adaptimmune news and features for those working in and with pharma, biotech and healthcare.

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Lyell’s technology will be used to improve GSK’s cell therapy candidates, including GSK3377794, which targets the NY-ESO-1 antigen and was originally developed by Austrian biotech Adaptimmune as

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific peptide-enhanced affinity receptor T cell immunotherapies in solid and haematological cancers.

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2).

  • Pharma deals during June 2014 Pharma deals during June 2014

    Of course the growth area within oncology is the immunological approach and GSK closed a $350m co-development and option deal with Adaptimmune. ... Adaptimmune develops TCR engineered T-cells and the agreement focuses on co-development around the cancer

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    Dr Jonathan Knowles, chairman of Adaptimmune, said: “I am delighted that such a high caliber individual as Larry Alleva has agreed to join our board of directors. ... Alleva's appointment follows a brace of recent senior hires that saw Adaptimmune

  • Adaptimmune appoints former GSK executives Adaptimmune appoints former GSK executives

    Dr Amado said: “I am pleased to be joining Adaptimmune at this exciting time. ... Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics